CureVac

mRNA Therapeutics and mRNA Vaccines Market by Route of Administration, Therapeutic Area, and Geography : Global Trends and Industry Analysis, 2022-2035

Retrieved on: 
Friday, November 18, 2022

In addition, over 1,000 mRNA therapeutics are being evaluated in various stages of clinical trials for the treatment of multitude of disease indications.

Key Points: 
  • In addition, over 1,000 mRNA therapeutics are being evaluated in various stages of clinical trials for the treatment of multitude of disease indications.
  • What are the current opportunities in the mRNA therapeutics and vaccines market?
  • In the past few years, the field of mRNA therapeutics and vaccines has evolved at a steady pace.
  • What are the recent developments and expected trends in the mRNA therapeutics and vaccines industry?

EQS-News: CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Retrieved on: 
Friday, November 11, 2022

TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.

Key Points: 
  • TBINGEN, Germany/ Boston, USA November 11, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced data from the Phase 1 expansion study of CV8102, the companys non-coding RNA candidate in oncology.
  • Preliminary results from the completed Phase 1 expansion study in patients with PD-1 refractory melanoma confirm a robust safety profile of CV8102 as a single agent and in combination with anti-PD-1 antibodies.
  • The data we collected in the heavily pretreated patients of our Phase 1 expansion study further confirm the safety and immuno-modulatory activity of CV8102, said Ulrike Gnad-Vogt, interim Chief Development Officer at CureVac.
  • The Phase 1, open-label, dose escalation and expansion study of CV8102 aims to assess safety, tolerability and efficacy of CV8102 as a single agent and in combination with licensed PD1-antibodies.

EQS-News: CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

Retrieved on: 
Friday, November 11, 2022

Examples include discussion of the potential efficacy of the companys vaccine and treatment candidates and the companys strategies, financing plans, growth opportunities and market growth.

Key Points: 
  • Examples include discussion of the potential efficacy of the companys vaccine and treatment candidates and the companys strategies, financing plans, growth opportunities and market growth.
  • Forward-looking statements are based on managements current beliefs and assumptions and on information currently available to the company.
  • However, these forward-looking statements are not a guarantee of the companys performance, and you should not place undue reliance on such statements.
  • Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.

mRNA Cancer Therapies Patent Landscape 2022: Description and Analysis of Key Players, Patents & Trends

Retrieved on: 
Monday, October 17, 2022

DUBLIN, Oct. 17, 2022 /PRNewswire/ -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 17, 2022 /PRNewswire/ -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering.
  • In cancer immunotherapy, the most advanced application of mRNA is therapeutic vaccination with mRNA encoding antigens, i.e., direct cancer vaccines or dendritic cell vaccines.
  • mRNA cancer therapies have been investigated and the selected patent families are labelled according to the technologies to which they relate.
  • The patent portfolio analysis of key players includes a description of the assignee, key numbers in terms of patents, time evolution of patent publication, main geographical coverage and live patents by technical segment.

mRNA Cancer Therapies Patent Landscape 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022

The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering.
  • In cancer immunotherapy, the most advanced application of mRNA is therapeutic vaccination with mRNA encoding antigens, i.e., direct cancer vaccines or dendritic cell vaccines.
  • mRNA cancer therapies have been investigated and the selected patent families are labelled according to the technologies to which they relate.
  • Among the players owning patent families related to mRNA cancer therapies, 50 newcomers were identified.

DGAP-News: CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, August 18, 2022

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Key Points: 
  • CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
    The issuer is solely responsible for the content of this announcement.
  • The CV0501 study follows the start of a Phase 1 study in March 2022 that evaluates an unmodified second-generation COVID-19 vaccine candidate CV2CoV, encoding for the original virus variant.
  • The comprehensive approach to evaluate both an unmodified and a modified, second-generation vaccine candidate against COVID-19 is expected to identify the best-performing candidate for later-stage clinical development.
  • CV0501 is CureVacs first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK.

DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Retrieved on: 
Thursday, August 18, 2022

In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.

Key Points: 
  • In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.
  • Moving into the second half of 2022, we are further broadening our mRNA technology platform and advancing our programs in prophylactic vaccines as well as executing on our core strategy in oncology.
  • CureVac is delivering on its previously announced 2022 clinical development program in prophylactic vaccines by initiating a Phase 1 study with the modified COVID-19 mRNA vaccine candidate CV0501.
  • In the first quarter of 2022, CureVac received a 10 million milestone payment related to the start of the seasonal influenza clinical trial.

Arix Bioscience plc Announces Changes to Board of Directors

Retrieved on: 
Wednesday, August 10, 2022

Dr Debra Barker appointed as Senior Independent Director, replacing Sir Michael Bunbury

Key Points: 
  • Dr Debra Barker appointed as Senior Independent Director, replacing Sir Michael Bunbury
    LONDON, 10 August 2022: Arix Bioscience plc (Arix or the Company) (LSE: ARIX), is pleased to announce the appointments of Dr Debra Barker, Dr Benny Soffer, and Andrew Smith as Senior Independent Director and Non-Executive Directors respectively with immediate effect.
  • In light of these appointments which bring the Board into compliance with the UK Corporate Governance Code, Sir Michael Bunbury is resigning from the Board with immediate effect.
  • Debra is currently Non-Executive Director of three publicly listed biotechnology companies: Destiny Pharma plc, BergenBio in Norway and most recently, CureVac AG in Germany.
  • Peregrine Moncreiffe, Chairman of the Board of Arix, said: We are delighted to welcome Debra, Benny and Andrew to the Board.

mRNA Platform Global Market Report 2022: Featuring Key Players BioNTech, Moderna, CureVac & Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 13, 2022

The "mRNA Platform - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "mRNA Platform - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Currently, of the total 44 ongoing clinical trials of mRNA vaccines, 23 of them are aimed at infectious diseases.
  • Cancer research has used mRNA platform to trigger the immune system to target specific cancer cells.
  • mRNA can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins.

DGAP-News: CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Retrieved on: 
Tuesday, July 5, 2022

CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.

Key Points: 
  • CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.
  • The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTechs SARS CoV-2 mRNA vaccine, among others.
  • CureVac considers the rapid development of these vaccines a tremendous achievement, with unprecedented positive impact for global public health.
  • This achievement is based on decades of scientific research and innovation, supported by CureVac as the earliest pioneer in mRNA technology.